Persistent pulmonary hypertension of the newborn. The black box revisited.
Our understanding and therapy of PPHN, as in many other aspects of neonatology, have been clouded by our understandable fear for our patients and our wish to provide excellent care. We can no longer accept therapies that are well intentioned but unstudied. It is time that thoughtful, well-designed studies be conducted to lead us into the next century. The controversies surrounding treatment can be answered in multicentered trials. We must accept this challenge.
Walsh-Sukys
M C
MC
Case Western Reserve University School of Medicine, Cleveland, Ohio.
D015199:Extracorporeal Membrane Oxygenation; D006801:Humans; D007231:Infant, Newborn; D010547:Persistent Fetal Circulation Syndrome / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D012121:Respiration, Artificial / Q000379:methods; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000627:therapeutic use
D014665:Vasodilator Agents